This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winkle, R. A. Articles by Harrison, D. C. Search for Related Content PubMed PubMed Citation Articles by Winkle, R. A. Articles by Harrison, D. C.

Circulation, Vol 54, 885-889, Copyright © 1976 by American Heart Association

ARTICLES

Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide

RA Winkle, PJ Meffin, JW Fitzgerald and DC Harrison

Tocainide, a new oral antiarrhythmic agent, was studied in man in a short-term protocol designed to evaluate the efficacy, kinetics, and toxicity of this compound. Premature ventricular contractions (PVCs) were suppressed by less than 70% in 11 of 15 patients compared with pre- drug placebo controls. For these 11 responders, there was an average PVC reduction of 91% +/- 10 (range 70 to 100%) at tocainide doses not associated with side effects. Mild transient central nervous system toxicity was observed in some patients near the time of peak concentrations during the highest dose administered. The drug was found to have linear kinetics over the dose range studied and a plasma half- life of 13.5 +/- 2 hours. Plasma concentration-response curves indicate antiarrhythmic activity over all plasma concentrations, with 70% PVC reduction above 6.0 mug/ml. This study suggests that tocainide is a safe and effective antiarrhythmic agent during short-term administration and is worthy of further clinical trials.

This article has been cited by other articles:

				S. P. KUTALEK, J. MORGANROTH, and L. N. HOROWITZ Tocainide: A New Oral Antiarrhythmic Agent Ann Intern Med, September 1, 1985; 103(3): 387 - 391. [Abstract] [PDF]